A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

por Johansen, Pierre, Sandberg, Anna, Capehorn, Matthew
Publicado 2020

The Potential Role of Digital Health in Obesity Care

por Hinchliffe, Nigel, Capehorn, Matthew S., Bewick, Michael, Feenie, John
Publicado 2022

Once-Weekly Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

por Capehorn, Matthew, Ghani, Yasmin, Hindsberger, Charlotte, Johansen, Pierre, Jódar, Esteban
Publicado 2020

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

por Capehorn, Matthew, Hallén, Nino, Baker-Knight, James, Glah, Divina, Hunt, Barnaby
Publicado 2021

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

por Mosenzon, Ofri, Capehorn, Matthew S., De Remigis, Alessandra, Rasmussen, Søren, Weimers, Petra, Rosenstock, Julio
Publicado 2022

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

por Johansen, Pierre, Chubb, Barrie, Hunt, Barnaby, Malkin, Samuel J. P., Sandberg, Anna, Capehorn, Matthew
Publicado 2020

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

por Lingvay, Ildiko, Capehorn, Matthew S, Catarig, Andrei-Mircea, Johansen, Pierre, Lawson, Jack, Sandberg, Anna, Shaw, Robert, Paine, Abby
Publicado 2020

Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering Committee

por Capehorn, Matthew S., Hinchliffe, Nigel, Cook, Deborah, Hill, Andrew, O’Kane, Mary, Tahrani, Abd A., Vincent, Ann, Williams, Simon, Feenie, John
Publicado 2022

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

por Bain, Stephen C., Hansen, Brian B., Malkin, Samuel J. P., Nuhoho, Solomon, Valentine, William J., Chubb, Barrie, Hunt, Barnaby, Capehorn, Matthew
Publicado 2019

Costs of the COVID‐19 pandemic associated with obesity in Europe: A health‐care cost model

por Czernichow, Sebastien, Bain, Stephen C., Capehorn, Matthew, Bøgelund, Mette, Madsen, Maria Elmegaard, Yssing, Cecilie, McMillan, Annabell Cajus, Cancino, Ana‐Paula, Panton, Ulrik Haagen
Publicado 2021

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 tr...

por Aroda, Vanita R., Capehorn, Matthew S., Chaykin, Louis, Frias, Juan P., Lausvig, Nanna L., Macura, Stanislava, Lüdemann, Jörg, Madsbad, Sten, Rosenstock, Julio, Tabak, Omur, Tadayon, Sayeh, Bain, Stephen C.
Publicado 2019